Journal
CLINICS IN LIVER DISEASE
Volume 22, Issue 1, Pages 189-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.cld.2017.08.013
Keywords
NAFLD; NASH; Obeticholic acid; Elafibranor; Liraglutide; Cenicriviroc; Selonsertib
Categories
Funding
- NIH
- Cirius (Octeta) Therapeutics
- Galmed
- Zydus
- Intercept
- Lilly
- Gilead
- Galectin Therapeutics
- Cumberland
Ask authors/readers for more resources
This article discusses completed phase II randomized clinical trials with high-quality published results for compounds that demonstrate effects on nonalcoholic steatohepatitis histology (obeticholic acid, elafibranor, and liraglutide). The authors also review the available preliminary data on cenicriviroc and selonsertib, with or without simtuzumab's phase II studies. Finally, the authors briefly discuss compounds that have been tested but did not achieve the primary end point of histologic improvement and appeared in high-quality published articles (cysteamine bitartrate and long-chain polyunsaturated fatty acids).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available